Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 421 to 432 of 432 entries
Sorted by: Best Match Show Resources per page
Clinical usefulness of cell-free and concentrated ascites reinfusion therapy (CART) in combination with chemotherapy for malignant ascites: a post-marketing surveillance study.

International journal of clinical oncology

Ishitani K, Isoai A, Ito T, Sugiyama H, Arakawa A, Yamada Y, Onodera H, Kobayashi R, Torii N, Soneda N, Matsuno Y, Utsugisawa T, Kato M, Hanafusa N.
PMID: 33761026
Int J Clin Oncol. 2021 Jun;26(6):1130-1138. doi: 10.1007/s10147-021-01883-2. Epub 2021 Mar 24.

BACKGROUND: Cell-free and concentrated ascites reinfusion therapy (CART) has been suggested to be able to treat malignant ascites more safely and effectively with chemotherapy because of its ability to retain serum protein and albumin. Although the characteristics of cancer...

Cite
Ishitani K, Isoai A, Ito T, et al. Clinical usefulness of cell-free and concentrated ascites reinfusion therapy (CART) in combination with chemotherapy for malignant ascites: a post-marketing surveillance study. Int J Clin Oncol. 2021;26(6):1130-1138doi: 10.1007/s10147-021-01883-2.
Ishitani, K., Isoai, A., Ito, T., Sugiyama, H., Arakawa, A., Yamada, Y., Onodera, H., Kobayashi, R., Torii, N., Soneda, N., Matsuno, Y., Utsugisawa, T., Kato, M., & Hanafusa, N. (2021). Clinical usefulness of cell-free and concentrated ascites reinfusion therapy (CART) in combination with chemotherapy for malignant ascites: a post-marketing surveillance study. International journal of clinical oncology, 26(6), 1130-1138. https://doi.org/10.1007/s10147-021-01883-2
Ishitani, Ken, et al. "Clinical usefulness of cell-free and concentrated ascites reinfusion therapy (CART) in combination with chemotherapy for malignant ascites: a post-marketing surveillance study." International journal of clinical oncology vol. 26,6 (2021): 1130-1138. doi: https://doi.org/10.1007/s10147-021-01883-2
Ishitani K, Isoai A, Ito T, Sugiyama H, Arakawa A, Yamada Y, Onodera H, Kobayashi R, Torii N, Soneda N, Matsuno Y, Utsugisawa T, Kato M, Hanafusa N. Clinical usefulness of cell-free and concentrated ascites reinfusion therapy (CART) in combination with chemotherapy for malignant ascites: a post-marketing surveillance study. Int J Clin Oncol. 2021 Jun;26(6):1130-1138. doi: 10.1007/s10147-021-01883-2. Epub 2021 Mar 24. PMID: 33761026.
Copy Download .nbib Format: NLM
[Low-grade (polymorphous) adenocarcinoma of the middle ear mimicking a jugulotympanic paraganglioma. German version].

HNO

Mantsopoulos K, Taha L, Fietkau R, Hornung J, Agaimy A, Iro H.
PMID: 33907857
HNO. 2021 Apr 27; doi: 10.1007/s00106-021-01027-y. Epub 2021 Apr 27.

A 64-year-old female patient presented with otalgia and hearing loss in the right ear. On otoscopy, the right tympanic membrane was highly vascularized and bulged into the anteroinferior quadrant. High-resolution computed tomography revealed an osteolytic lesion with occupation of...

Cite
Mantsopoulos K, Taha L, Fietkau R, et al. (Polymorphes) Low-Grade-Adenokarzinom des Mittelohrs als Imitator eines jugulotympanalen Paraganglioms. [Low-grade (polymorphous) adenocarcinoma of the middle ear mimicking a jugulotympanic paraganglioma. German version]. HNO. 2021;doi: 10.1007/s00106-021-01027-y.
Mantsopoulos, K., Taha, L., Fietkau, R., Hornung, J., Agaimy, A., & Iro, H. (2021). (Polymorphes) Low-Grade-Adenokarzinom des Mittelohrs als Imitator eines jugulotympanalen Paraganglioms. [Low-grade (polymorphous) adenocarcinoma of the middle ear mimicking a jugulotympanic paraganglioma. German version]. HNO, . https://doi.org/10.1007/s00106-021-01027-y
Mantsopoulos, Konstantinos, et al. "(Polymorphes) Low-Grade-Adenokarzinom des Mittelohrs als Imitator eines jugulotympanalen Paraganglioms." [Low-grade (polymorphous) adenocarcinoma of the middle ear mimicking a jugulotympanic paraganglioma. German version]. HNO vol. (2021). doi: https://doi.org/10.1007/s00106-021-01027-y
Mantsopoulos K, Taha L, Fietkau R, Hornung J, Agaimy A, Iro H. (Polymorphes) Low-Grade-Adenokarzinom des Mittelohrs als Imitator eines jugulotympanalen Paraganglioms. [Low-grade (polymorphous) adenocarcinoma of the middle ear mimicking a jugulotympanic paraganglioma. German version]. HNO. 2021 Apr 27; doi: 10.1007/s00106-021-01027-y. Epub 2021 Apr 27. German. PMID: 33907857.
Copy Download .nbib Format: NLM
Parents' Experiences with Home-Based Oral Chemotherapy Prescribed to a Child Diagnosed with Acute Lymphoblastic Leukemia: A Qualitative Study.

Current oncology (Toronto, Ont.)

Camiré-Bernier É, Nidelet E, Baghdadli A, Demers G, Boulanger MC, Brisson MC, Michon B, Lauzier S, Laverdière I.
PMID: 34898538
Curr Oncol. 2021 Nov 01;28(6):4377-4391. doi: 10.3390/curroncol28060372.

Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. Treatment includes home-based oral chemotherapies (OCs) (e.g., 6-mercaptopurine and dexamethasone) taken for 2 to 3 years. The management of OC can be challenging for children and...

Cite
Camiré-Bernier É, Nidelet E, Baghdadli A, et al. Parents' Experiences with Home-Based Oral Chemotherapy Prescribed to a Child Diagnosed with Acute Lymphoblastic Leukemia: A Qualitative Study. Curr Oncol. 2021;28(6):4377-4391doi: 10.3390/curroncol28060372.
Camiré-Bernier, �. �., Nidelet, E., Baghdadli, A., Demers, G., Boulanger, M. C., Brisson, M. C., Michon, B., Lauzier, S., & Laverdière, I. (2021). Parents' Experiences with Home-Based Oral Chemotherapy Prescribed to a Child Diagnosed with Acute Lymphoblastic Leukemia: A Qualitative Study. Current oncology (Toronto, Ont.), 28(6), 4377-4391. https://doi.org/10.3390/curroncol28060372
Camiré-Bernier, Étienne, et al. "Parents' Experiences with Home-Based Oral Chemotherapy Prescribed to a Child Diagnosed with Acute Lymphoblastic Leukemia: A Qualitative Study." Current oncology (Toronto, Ont.) vol. 28,6 (2021): 4377-4391. doi: https://doi.org/10.3390/curroncol28060372
Camiré-Bernier É, Nidelet E, Baghdadli A, Demers G, Boulanger MC, Brisson MC, Michon B, Lauzier S, Laverdière I. Parents' Experiences with Home-Based Oral Chemotherapy Prescribed to a Child Diagnosed with Acute Lymphoblastic Leukemia: A Qualitative Study. Curr Oncol. 2021 Nov 01;28(6):4377-4391. doi: 10.3390/curroncol28060372. PMID: 34898538; PMCID: PMC8628767.
Copy Download .nbib Format: NLM
Occupational exposure to antineoplastic drugs: what about hospital sanitation personnel?.

International archives of occupational and environmental health

Labrèche F, Ouellet C, Roberge B, Caron NJ, Yennek A, Bussières JF.
PMID: 34410477
Int Arch Occup Environ Health. 2021 Nov;94(8):1877-1888. doi: 10.1007/s00420-021-01731-w. Epub 2021 Aug 19.

OBJECTIVE: Occupational exposure to antineoplastic drugs (ANPs) occurs mainly through dermal contact. Our study was set up to assess the potential exposure of hospital sanitation (HS) personnel, for whom almost no data are available, through contamination of surfaces they...

Cite
Labrèche F, Ouellet C, Roberge B, et al. Occupational exposure to antineoplastic drugs: what about hospital sanitation personnel?. Int Arch Occup Environ Health. 2021;94(8):1877-1888doi: 10.1007/s00420-021-01731-w.
Labrèche, F., Ouellet, C., Roberge, B., Caron, N. J., Yennek, A., & Bussières, J. F. (2021). Occupational exposure to antineoplastic drugs: what about hospital sanitation personnel?. International archives of occupational and environmental health, 94(8), 1877-1888. https://doi.org/10.1007/s00420-021-01731-w
Labrèche, France, et al. "Occupational exposure to antineoplastic drugs: what about hospital sanitation personnel?." International archives of occupational and environmental health vol. 94,8 (2021): 1877-1888. doi: https://doi.org/10.1007/s00420-021-01731-w
Labrèche F, Ouellet C, Roberge B, Caron NJ, Yennek A, Bussières JF. Occupational exposure to antineoplastic drugs: what about hospital sanitation personnel?. Int Arch Occup Environ Health. 2021 Nov;94(8):1877-1888. doi: 10.1007/s00420-021-01731-w. Epub 2021 Aug 19. PMID: 34410477.
Copy Download .nbib Format: NLM
Usefulness of cyclic thermal therapy and red blood cell scintigraphy in patients with chemotherapy-induced peripheral neuropathy.

The Korean journal of pain

Kim M, Kim EM, Oh PS, Lim ST, Sohn MH, Song EK, Park KU, Kim JY, Won KS, Jeong HJ.
PMID: 34593660
Korean J Pain. 2021 Oct 01;34(4):427-436. doi: 10.3344/kjp.2021.34.4.427.

BACKGROUND: Pharmacological and non-pharmacological therapies have been used to treat patients with chemotherapy-induced peripheral neuropathy (CIPN). However, the effect of therapies in cancer patients has yet to be investigated comprehensively. We hypothesized that cyclic thermal therapy would improve blood...

Cite
Kim M, Kim EM, Oh PS, et al. Usefulness of cyclic thermal therapy and red blood cell scintigraphy in patients with chemotherapy-induced peripheral neuropathy. Korean J Pain. 2021;34(4):427-436doi: 10.3344/kjp.2021.34.4.427.
Kim, M., Kim, E. M., Oh, P. S., Lim, S. T., Sohn, M. H., Song, E. K., Park, K. U., Kim, J. Y., Won, K. S., & Jeong, H. J. (2021). Usefulness of cyclic thermal therapy and red blood cell scintigraphy in patients with chemotherapy-induced peripheral neuropathy. The Korean journal of pain, 34(4), 427-436. https://doi.org/10.3344/kjp.2021.34.4.427
Kim, Minjoo, et al. "Usefulness of cyclic thermal therapy and red blood cell scintigraphy in patients with chemotherapy-induced peripheral neuropathy." The Korean journal of pain vol. 34,4 (2021): 427-436. doi: https://doi.org/10.3344/kjp.2021.34.4.427
Kim M, Kim EM, Oh PS, Lim ST, Sohn MH, Song EK, Park KU, Kim JY, Won KS, Jeong HJ. Usefulness of cyclic thermal therapy and red blood cell scintigraphy in patients with chemotherapy-induced peripheral neuropathy. Korean J Pain. 2021 Oct 01;34(4):427-436. doi: 10.3344/kjp.2021.34.4.427. PMID: 34593660; PMCID: PMC8494953.
Copy Download .nbib Format: NLM
Chemotherapy Treatments for Burkitt Lymphoma: Systematic Review of Interventional Studies.

Clinical lymphoma, myeloma & leukemia

Della Rocca AM, Leonart LP, Ferreira VL, Tonin FS, Steffenello-Durigon G, Del Moral JAG, Fernandez-Llimos F, Pontarolo R.
PMID: 33947633
Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):514-525. doi: 10.1016/j.clml.2021.03.012. Epub 2021 Apr 03.

BACKGROUND: Burkitt lymphoma (BL) is an aggressive hematologic cancer. This study synthetized the evidence about the efficacy and safety of chemotherapy treatments used in patients with BL using the World Health Organization classification.MATERIALS AND METHODS: A systematic review of...

Cite
Della Rocca AM, Leonart LP, Ferreira VL, et al. Chemotherapy Treatments for Burkitt Lymphoma: Systematic Review of Interventional Studies. Clin Lymphoma Myeloma Leuk. 2021;21(8):514-525doi: 10.1016/j.clml.2021.03.012.
Della Rocca, A. M., Leonart, L. P., Ferreira, V. L., Tonin, F. S., Steffenello-Durigon, G., Del Moral, J. A. G., Fernandez-Llimos, F., & Pontarolo, R. (2021). Chemotherapy Treatments for Burkitt Lymphoma: Systematic Review of Interventional Studies. Clinical lymphoma, myeloma & leukemia, 21(8), 514-525. https://doi.org/10.1016/j.clml.2021.03.012
Della Rocca, Ana M, et al. "Chemotherapy Treatments for Burkitt Lymphoma: Systematic Review of Interventional Studies." Clinical lymphoma, myeloma & leukemia vol. 21,8 (2021): 514-525. doi: https://doi.org/10.1016/j.clml.2021.03.012
Della Rocca AM, Leonart LP, Ferreira VL, Tonin FS, Steffenello-Durigon G, Del Moral JAG, Fernandez-Llimos F, Pontarolo R. Chemotherapy Treatments for Burkitt Lymphoma: Systematic Review of Interventional Studies. Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):514-525. doi: 10.1016/j.clml.2021.03.012. Epub 2021 Apr 03. PMID: 33947633.
Copy Download .nbib Format: NLM
Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease.

The oncologist

Wong RL, Ferris LA, Do OA, Holt SK, Ramos JD, Crabb SJ, Sternberg CN, Bellmunt J, Ladoire S, De Giorgi U, Harshman LC, Vaishampayan UN, Necchi A, Srinivas S, Pal SK, Niegisch G, Dorff TB, Galsky MD, Yu EY.
PMID: 34355457
Oncologist. 2021 Dec;26(12):1026-1034. doi: 10.1002/onco.13925. Epub 2021 Aug 17.

BACKGROUND: Fit patients with metastatic urothelial carcinoma (mUC) receive first-line platinum-based combination chemotherapy (fPBC) as standard of care and may receive additional later-line chemotherapy after progression. Our study compares outcomes with subsequent platinum-based chemotherapy (sPBC) versus subsequent non-platinum-based chemotherapy...

Cite
Wong RL, Ferris LA, Do OA, et al. Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease. Oncologist. 2021;26(12):1026-1034doi: 10.1002/onco.13925.
Wong, R. L., Ferris, L. A., Do, O. A., Holt, S. K., Ramos, J. D., Crabb, S. J., Sternberg, C. N., Bellmunt, J., Ladoire, S., De Giorgi, U., Harshman, L. C., Vaishampayan, U. N., Necchi, A., Srinivas, S., Pal, S. K., Niegisch, G., Dorff, T. B., Galsky, M. D., & Yu, E. Y. (2021). Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease. The oncologist, 26(12), 1026-1034. https://doi.org/10.1002/onco.13925
Wong, Risa L, et al. "Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease." The oncologist vol. 26,12 (2021): 1026-1034. doi: https://doi.org/10.1002/onco.13925
Wong RL, Ferris LA, Do OA, Holt SK, Ramos JD, Crabb SJ, Sternberg CN, Bellmunt J, Ladoire S, De Giorgi U, Harshman LC, Vaishampayan UN, Necchi A, Srinivas S, Pal SK, Niegisch G, Dorff TB, Galsky MD, Yu EY. Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease. Oncologist. 2021 Dec;26(12):1026-1034. doi: 10.1002/onco.13925. Epub 2021 Aug 17. PMID: 34355457.
Copy Download .nbib Format: NLM
Phase 1 study of pembrolizumab plus chemotherapy as first-line treatment in Japanese patients with advanced NSCLC.

Cancer treatment and research communications

Kurata T, Nakagawa K, Satouchi M, Seto T, Sawada T, Han S, Homma M, Noguchi K, Nogami N.
PMID: 34607222
Cancer Treat Res Commun. 2021 Sep 15;29:100458. doi: 10.1016/j.ctarc.2021.100458. Epub 2021 Sep 15.

INTRODUCTION: Pembrolizumab plus chemotherapy significantly improved outcomes over chemotherapy alone as first-line treatment in patients with advanced non-small-cell lung cancer (NSCLC) in phase 3 international trials. In the phase 1 KEYNOTE-011 study (parts B and C), we evaluated the...

Cite
Kurata T, Nakagawa K, Satouchi M, et al. Phase 1 study of pembrolizumab plus chemotherapy as first-line treatment in Japanese patients with advanced NSCLC. Cancer Treat Res Commun. 2021;29:100458doi: 10.1016/j.ctarc.2021.100458.
Kurata, T., Nakagawa, K., Satouchi, M., Seto, T., Sawada, T., Han, S., Homma, M., Noguchi, K., & Nogami, N. (2021). Phase 1 study of pembrolizumab plus chemotherapy as first-line treatment in Japanese patients with advanced NSCLC. Cancer treatment and research communications, 29100458. https://doi.org/10.1016/j.ctarc.2021.100458
Kurata, Takayasu, et al. "Phase 1 study of pembrolizumab plus chemotherapy as first-line treatment in Japanese patients with advanced NSCLC." Cancer treatment and research communications vol. 29 (2021): 100458. doi: https://doi.org/10.1016/j.ctarc.2021.100458
Kurata T, Nakagawa K, Satouchi M, Seto T, Sawada T, Han S, Homma M, Noguchi K, Nogami N. Phase 1 study of pembrolizumab plus chemotherapy as first-line treatment in Japanese patients with advanced NSCLC. Cancer Treat Res Commun. 2021 Sep 15;29:100458. doi: 10.1016/j.ctarc.2021.100458. Epub 2021 Sep 15. PMID: 34607222.
Copy Download .nbib Format: NLM
Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma.

Cancer medicine

Yu KH, Ozer M, Cockrum P, Surinach A, Wang S, Chu BC.
PMID: 34811961
Cancer Med. 2021 Dec;10(24):8934-8943. doi: 10.1002/cam4.4415. Epub 2021 Nov 22.

BACKGROUND: Many real-world studies of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) are restricted to single centers, limiting the generalizability of their insights. This study aimed to identify important population-based predictors for survival in patients diagnosed with mPDAC in...

Cite
Yu KH, Ozer M, Cockrum P, et al. Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma. Cancer Med. 2021;10(24):8934-8943doi: 10.1002/cam4.4415.
Yu, K. H., Ozer, M., Cockrum, P., Surinach, A., Wang, S., & Chu, B. C. (2021). Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma. Cancer medicine, 10(24), 8934-8943. https://doi.org/10.1002/cam4.4415
Yu, Kenneth H, et al. "Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma." Cancer medicine vol. 10,24 (2021): 8934-8943. doi: https://doi.org/10.1002/cam4.4415
Yu KH, Ozer M, Cockrum P, Surinach A, Wang S, Chu BC. Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma. Cancer Med. 2021 Dec;10(24):8934-8943. doi: 10.1002/cam4.4415. Epub 2021 Nov 22. PMID: 34811961.
Copy Download .nbib Format: NLM
Development of a prediction models for chemotherapy-induced adverse drug reactions: A retrospective observational study using electronic health records.

European journal of oncology nursing : the official journal of European Oncology Nursing Society

On J, Park HA, Yoo S.
PMID: 34861529
Eur J Oncol Nurs. 2021 Nov 20;56:102066. doi: 10.1016/j.ejon.2021.102066. Epub 2021 Nov 20.

PURPOSE: Chemotherapy-induced adverse drug reactions (ADRs) are common and diverse, and not only affect changes or interruptions to treatment schedules, but also negatively affect the patient's quality of life. This study aimed to predict eight chemotherapy-induced ADRs based on...

Cite
On J, Park HA, Yoo S. Development of a prediction models for chemotherapy-induced adverse drug reactions: A retrospective observational study using electronic health records. Eur J Oncol Nurs. 2021;56:102066doi: 10.1016/j.ejon.2021.102066.
On, J., Park, H. A., & Yoo, S. (2021). Development of a prediction models for chemotherapy-induced adverse drug reactions: A retrospective observational study using electronic health records. European journal of oncology nursing : the official journal of European Oncology Nursing Society, 56102066. https://doi.org/10.1016/j.ejon.2021.102066
On, Jeongah, et al. "Development of a prediction models for chemotherapy-induced adverse drug reactions: A retrospective observational study using electronic health records." European journal of oncology nursing : the official journal of European Oncology Nursing Society vol. 56 (2021): 102066. doi: https://doi.org/10.1016/j.ejon.2021.102066
On J, Park HA, Yoo S. Development of a prediction models for chemotherapy-induced adverse drug reactions: A retrospective observational study using electronic health records. Eur J Oncol Nurs. 2021 Nov 20;56:102066. doi: 10.1016/j.ejon.2021.102066. Epub 2021 Nov 20. PMID: 34861529.
Copy Download .nbib Format: NLM
Medication guide for the perioperative management of oral antineoplastic agents in cancer patients.

Expert opinion on drug safety

Villanueva-Bueno C, Escudero-Vilaplana V, Collado-Borrell R, Giménez-Manzorro Á, Ribed A, Marzal-Alfaro B, Revuelta-Herrero JL, Gonzalez-Haba E, Herranz A, Sanjurjo M.
PMID: 34357828
Expert Opin Drug Saf. 2021 Aug 12;1-13. doi: 10.1080/14740338.2021.1965990. Epub 2021 Aug 12.

BACKGROUND: Oral antineoplastic agents (OAAs) are high-risk drugs that may increase the risk of bleeding, difficulty in wound healing, or produce alterations in coagulation and/or platelet aggregation. These aspects had to be highly considered throughout the entire perioperative process....

Cite
Villanueva-Bueno C, Escudero-Vilaplana V, Collado-Borrell R, et al. Medication guide for the perioperative management of oral antineoplastic agents in cancer patients. Expert Opin Drug Saf. 2021;1-13doi: 10.1080/14740338.2021.1965990.
Villanueva-Bueno, C., Escudero-Vilaplana, V., Collado-Borrell, R., Giménez-Manzorro, �. �., Ribed, A., Marzal-Alfaro, B., Revuelta-Herrero, J. L., Gonzalez-Haba, E., Herranz, A., & Sanjurjo, M. (2021). Medication guide for the perioperative management of oral antineoplastic agents in cancer patients. Expert opinion on drug safety, 1-13. https://doi.org/10.1080/14740338.2021.1965990
Villanueva-Bueno, Cristina, et al. "Medication guide for the perioperative management of oral antineoplastic agents in cancer patients." Expert opinion on drug safety vol. (2021): 1-13. doi: https://doi.org/10.1080/14740338.2021.1965990
Villanueva-Bueno C, Escudero-Vilaplana V, Collado-Borrell R, Giménez-Manzorro Á, Ribed A, Marzal-Alfaro B, Revuelta-Herrero JL, Gonzalez-Haba E, Herranz A, Sanjurjo M. Medication guide for the perioperative management of oral antineoplastic agents in cancer patients. Expert Opin Drug Saf. 2021 Aug 12;1-13. doi: 10.1080/14740338.2021.1965990. Epub 2021 Aug 12. PMID: 34357828.
Copy Download .nbib Format: NLM
Trends in Fenton and photo-Fenton processes for degradation of antineoplastic agents in water matrices: current knowledge and future challenges evaluation using a bibliometric and systematic analysis.

Environmental science and pollution research international

Sanabria P, Wilde ML, Ruiz-Padillo A, Sirtori C.
PMID: 34403053
Environ Sci Pollut Res Int. 2021 Aug 17; doi: 10.1007/s11356-021-15938-4. Epub 2021 Aug 17.

Antineoplastic agents present potential hazards to human health and the environment. For this reason, these compounds have attracted a great deal of attention from researchers in the environmental sciences field. In order to help guide future research, it is...

Cite
Sanabria P, Wilde ML, Ruiz-Padillo A, et al. Trends in Fenton and photo-Fenton processes for degradation of antineoplastic agents in water matrices: current knowledge and future challenges evaluation using a bibliometric and systematic analysis. Environ Sci Pollut Res Int. 2021;doi: 10.1007/s11356-021-15938-4.
Sanabria, P., Wilde, M. L., Ruiz-Padillo, A., & Sirtori, C. (2021). Trends in Fenton and photo-Fenton processes for degradation of antineoplastic agents in water matrices: current knowledge and future challenges evaluation using a bibliometric and systematic analysis. Environmental science and pollution research international, . https://doi.org/10.1007/s11356-021-15938-4
Sanabria, Pedro, et al. "Trends in Fenton and photo-Fenton processes for degradation of antineoplastic agents in water matrices: current knowledge and future challenges evaluation using a bibliometric and systematic analysis." Environmental science and pollution research international vol. (2021). doi: https://doi.org/10.1007/s11356-021-15938-4
Sanabria P, Wilde ML, Ruiz-Padillo A, Sirtori C. Trends in Fenton and photo-Fenton processes for degradation of antineoplastic agents in water matrices: current knowledge and future challenges evaluation using a bibliometric and systematic analysis. Environ Sci Pollut Res Int. 2021 Aug 17; doi: 10.1007/s11356-021-15938-4. Epub 2021 Aug 17. PMID: 34403053.
Copy Download .nbib Format: NLM
Showing 421 to 432 of 432 entries